Related Experiment Video
Updated: May 14, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
[Management of adverse events induced by TNFalpha blocking agents]
S Chappuis1, C Ribi, F Spertini
1Service d'immunologie et allergie, CHUV, 1011 Lausanne. samuel.chappuis@chuv.ch
Abstract:
TNFalpha blocking agents are effective and essential tools in the management of many inflammatory conditions including rheumatoid arthritis, spondylarthropathies and chronic inflammatory bowel disease. With time, some known side-effects have gained in importance and others have appeared. This article focuses on the potential risks of infection and autoimmunity induced by TNFalpha blocking agents and on the strategy to prevent and treat such adverse events.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Pericarditis III: Medical Management
